Merck & Co. Inc (6MK DU) stock market data APIs
€101.5082
-0.34(-0.3%)
as of February 13, 2026
Try our APIs with
free plan!
Merck & Co. Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 6MK.DU.
Prev. Close
101.5082
Open
101.1662
High
102.3456
Low
99.2981
52 wk Range
63.6808-103.2
Market Cap
162 424 M
Dividends (Yield)
0.0233
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merck & Co. Inc data using free add-ons & libraries
Get Merck & Co. Inc Fundamental Data
Merck & Co. Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-03
- EPS/Forecast: 2.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Co. Inc News
New
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut
By Atharva Singh and Arasu Kannagi Basil Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5...
Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?
Biotech bigwig Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, after market close. The Zacks Consensus Estimate for fourth-quarter sales and ear...
AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?
AstraZeneca AZN is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 4.39%...
Rapid Innovation is Reshaping Oncology: Stocks in Focus
An updated edition of the December 17, 2025, article. The global oncology market is entering a phase of accelerated transformation, driven by rising cancer incidence, demographic shifts and rapid sci...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
